William E. Aliski's most recent trade in X4 Pharmaceuticals Inc was a trade of 45,000 Common Stock done . Disclosure was reported to the exchange on June 10, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharma Inc | William E. Aliski | Director | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | ||
| X4 Pharma Inc | William E. Aliski | Director | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | William E. Aliski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 4,125 | 4,125 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical Inc | William E. Aliski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 2,145 | 66,849 (0%) | 0% | 0 | Common Stock | |
| X4 Pharma Inc | William E. Aliski | Director | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) |